Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...

TOKYO-Nintendo's new Switch 2 videogame machine uses a rare-earth magnet to attach its hand-held controllers to the main console, according to a teardown, highlighting the company's vulnerability to ...

A new study says the health of American children has gotten worse across the board in the last 17 years. Published in the ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...